TB
The startup develops synthetic live biotherapeutic drugs that utilize engineered probiotics to provide targeted therapeutic activities against diseases resistant to conventional treatments. By addressing bacterial resistance and enhancing treatment efficacy, the company enables healthcare providers to offer effective solutions for conditions that traditional pharmaceuticals cannot manage.
Updated 3 months ago
Funding
$330K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops synthetic live biotherapeutic drugs that utilize engineered probiotics to provide targeted therapeutic activities against diseases resistant to conventional treatments. By addressing bacterial resistance and enhancing treatment efficacy, the company enables healthcare providers to offer effective solutions for conditions that traditional pharmaceuticals cannot manage.